DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,042 filers reported holding DANAHER CORPORATION in Q3 2023. The put-call ratio across all filers is 0.89 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,923,570 | +3.4% | 31,937 | 0.0% | 1.71% | +6.7% |
| Q2 2023 | $7,664,880 | -5.0% | 31,937 | -0.2% | 1.60% | -12.1% |
| Q1 2023 | $8,064,524 | -5.0% | 31,997 | 0.0% | 1.82% | -8.7% |
| Q4 2022 | $8,492,644 | +2.8% | 31,997 | 0.0% | 1.99% | -5.3% |
| Q3 2022 | $8,265,000 | +36.2% | 31,997 | +33.7% | 2.10% | +44.3% |
| Q2 2022 | $6,067,000 | -13.6% | 23,930 | 0.0% | 1.46% | +2.2% |
| Q1 2022 | $7,019,000 | -10.8% | 23,930 | 0.0% | 1.43% | -7.2% |
| Q4 2021 | $7,873,000 | +8.1% | 23,930 | 0.0% | 1.54% | -29.8% |
| Q3 2021 | $7,285,000 | +13.4% | 23,930 | 0.0% | 2.19% | +60.7% |
| Q2 2021 | $6,422,000 | +19.2% | 23,930 | 0.0% | 1.36% | +7.1% |
| Q1 2021 | $5,386,000 | +1.3% | 23,930 | 0.0% | 1.28% | -7.2% |
| Q4 2020 | $5,316,000 | +3.2% | 23,930 | 0.0% | 1.37% | -7.3% |
| Q3 2020 | $5,153,000 | +21.1% | 23,930 | -0.5% | 1.48% | +10.3% |
| Q2 2020 | $4,255,000 | +26.6% | 24,060 | -0.9% | 1.34% | +5.7% |
| Q1 2020 | $3,361,000 | -9.7% | 24,280 | +0.1% | 1.27% | +18.3% |
| Q4 2019 | $3,723,000 | +6.2% | 24,260 | 0.0% | 1.08% | -4.1% |
| Q3 2019 | $3,504,000 | +9.7% | 24,260 | +0.3% | 1.12% | +8.4% |
| Q1 2019 | $3,194,000 | +28.1% | 24,190 | 0.0% | 1.04% | +15.1% |
| Q4 2018 | $2,494,000 | +4.5% | 24,190 | 0.0% | 0.90% | +23.0% |
| Q2 2018 | $2,387,000 | +0.8% | 24,190 | 0.0% | 0.73% | 0.0% |
| Q1 2018 | $2,368,000 | +5.0% | 24,190 | -0.5% | 0.73% | +6.4% |
| Q4 2017 | $2,256,000 | +5.2% | 24,300 | -2.8% | 0.69% | +0.7% |
| Q3 2017 | $2,145,000 | -23.8% | 25,010 | -25.1% | 0.68% | -26.7% |
| Q2 2017 | $2,816,000 | -1.3% | 33,370 | 0.0% | 0.93% | -1.4% |
| Q1 2017 | $2,854,000 | +2.5% | 33,370 | -6.7% | 0.94% | -0.8% |
| Q4 2016 | $2,785,000 | -0.7% | 35,776 | 0.0% | 0.95% | -4.2% |
| Q3 2016 | $2,804,000 | -22.4% | 35,776 | -0.1% | 0.99% | -21.5% |
| Q2 2016 | $3,615,000 | +5.3% | 35,796 | -1.1% | 1.27% | +2.4% |
| Q1 2016 | $3,433,000 | +1.4% | 36,192 | -0.7% | 1.24% | +4.9% |
| Q4 2015 | $3,386,000 | +5.9% | 36,456 | -2.4% | 1.18% | +9.5% |
| Q2 2015 | $3,196,000 | +0.8% | 37,336 | 0.0% | 1.08% | -0.3% |
| Q1 2015 | $3,170,000 | -0.9% | 37,336 | 0.0% | 1.08% | -3.1% |
| Q4 2014 | $3,200,000 | +12.6% | 37,336 | -0.2% | 1.11% | +8.3% |
| Q3 2014 | $2,841,000 | -5.0% | 37,396 | -1.5% | 1.03% | +1.0% |
| Q2 2014 | $2,990,000 | -0.9% | 37,980 | -5.5% | 1.02% | -4.2% |
| Q1 2014 | $3,016,000 | -3.3% | 40,210 | -0.4% | 1.06% | -4.7% |
| Q4 2013 | $3,118,000 | +10.9% | 40,390 | -0.4% | 1.12% | +2.4% |
| Q3 2013 | $2,811,000 | +9.5% | 40,550 | -0.0% | 1.09% | +2.0% |
| Q2 2013 | $2,568,000 | – | 40,570 | – | 1.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |